ANGIOTECH PHARMACEUTICALS INC - FORM 10-K - EX-12 - STATEMENT RE COMPUTATION OF RATIOS - March 16, 2011

Attached files

file filename
10-K - FORM 10-K - ANGIOTECH PHARMACEUTICALS INCd10k.htm
EX-21 - LIST OF WORLDWIDE SUBSIDIARIES - ANGIOTECH PHARMACEUTICALS INCdex21.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO SECTION 302 - ANGIOTECH PHARMACEUTICALS INCdex311.htm
EX-23.1 - CONSENT OF PRICEWATERHOUSECOOPERS LLP - ANGIOTECH PHARMACEUTICALS INCdex231.htm
EX-32.1 - CERTIFICATION OF CEO PURSUANT TO SECTION 906 - ANGIOTECH PHARMACEUTICALS INCdex321.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO SECTION 302 - ANGIOTECH PHARMACEUTICALS INCdex312.htm
EX-32.2 - CERTIFICATION OF CFO PURSUANT TO SECTION 906 - ANGIOTECH PHARMACEUTICALS INCdex322.htm
EX-10.30 - EXECUTIVE EMPLOYMENT AGREEMENT - STEVE BRYANT - ANGIOTECH PHARMACEUTICALS INCdex1030.htm

EXHIBIT 12

ANGIOTECH

RATIO OF EARNINGS TO FIXED CHARGES

 

     Year Ended December 31,  
     2006      2007     2008     2009      2010  
     (Dollars in Thousands)  

Earnings:

             

Pre-tax income (loss) from continuing operations

    $ 20,115       $ (70,592 )    $ (754,068 )   $ (16,831 )     $ (66,885 ) 
                                          

Total Earnings

    $ 20,115       $ (70,592 )    $ (754,068 )   $ (16,831 )    $ (66,885 ) 
                                          

Fixed Charges:

             

Interest expense and amortization of capitalized expenses related to indebtedness

    $ 35,502       $ 51,748      $ 44,490      $ 38,039       $ 40,258   

Interest within rent expense

    $ 700       $ 800      $ 1,167      $ 1,067       $ 1,100   
                                          

Total Fixed Charges

    $ 36,202       $ 52,548      $ 45,657      $ 39,106       $ 41,358   
                                          

Pre-tax income (loss) from continuing operations plus fixed charges

    $ 56,317       $ (18,044 )    $ (708,411 )   $ 22,275       $ (25,527 ) 
                                          

Ratio of Earnings to Fixed Charges

      1.6         —   (1)     —   (1)     0.6        —   (1) 
                                          

Dollar amount of deficiency

      n/a       $ 70,592      $ 754,068      $ 16,831       $ 66,885   

 

(1)

Our earnings during this period were insufficient to cover fixed charges and, accordingly, ratios are not presented.

ANGIOTECH PHARMACEUTICALS INC Reports